Inhaled Colistin in Elderly Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa (PA) Bronchial Infection

Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review

“…We obtained data from the trials registry (ClinicalTrials.gov), congress presentations and drug company's trial reports to assess the eligibility of five unpublished trials. All five unpublished trials [21][22][23][24][25][26][27][28] met the inclusion criteria. No additional trials were found by checking the reference lists of primary studies and review articles.…”

“…No additional trials were found by checking the reference lists of primary studies and review articles. Thus, 12 trials [9,11,[21][22][23][24][25][26][27][28][29][30][31][32][33] were included in this review with eight [9,11,26,27,[29][30][31][32][33] contributing data to the meta-analysis ( fig. 1).…”

“…Table 1 summarises the characteristics of the 12 included trials. All but three studies [28,31,32] were randomised, double-blind, placebo-controlled trials and nine [9, 11, 21-27, 30, 31, 33] were multicentre studies. Eight trials [9, 11, 21-27, 31, 33] were sponsored by pharmaceutical companies.…”

“…In the remaining four unpublished trials with a total of 674 patients, we failed to obtain suitable data for metaanalysis. We have narratively summarised the main findings of these four trials in online supplementary table S1 [21][22][23][24][25]28].…”

“…The primary efficacy outcome included mean change in sputum bacterial load (log 10 CFU?g -1 ) [9,11,24,25,31,33], time to first exacerbation or number of exacerbations [29,30], mean change in quality of life scores [21][22][23] and need for hospital readmissions [28]. One safety trial [26,27] used incidence of adverse events as the primary outcome.…”